Search Resources (English): Health protection

Results 1 - 10 of 34

Results

Registering the impact of breast implants  
http://www.cwhn.ca/sites/default/files/PDF/CEWH/RB/bulletin-vol3no2EN.pdf

Examines the questions surrounding breast implant safety and mechanisms to track patients over time.

 (See Details)
Published: 2003
Hormone therapy: health protection lessons from the Women's Health Initiative  
http://www.cwhn.ca/sites/default/files/PDF/CEWH/RB/bulletin-vol3no2EN.pdf

Examines the results of the Women's Health Initiative (WHI) study regarding hormone replacement therapy.

 (See Details)
Published: 2003
International harmonisation of new drugs regulation: not in women's best interest  
http://www.cwhn.ca/sites/default/files/PDF/CEWH/RB/bulletin-vol3no2EN.pdf

Examines the question of harmonisation of pharmaceutical regulation and its implications for women and public health. Urges that safety standards be paramount and the particular needs of women and other groups are not lost.

 (See Details)
Published: 2003
Safety first: women and health protection  
http://www.cwhn.ca/sites/default/files/PDF/CEWH/RB/bulletin-vol3no2EN.pdf

Presents cautions to regulators, consumers, practitioners, and researchers to learn from the past in order to protect women’s health in the future.

 (See Details)
Published: 2003
Women and adverse drug reactions: reporting in the Canadian context  
http://www.cwhn.ca/sites/default/files/PDF/CEWH/RB/bulletin-vol3no2EN.pdf

Examines the Canadian system of adverse drug reactions reporting and that women’s particular susceptibilities to drug-related health risks must be taken into consideration.

 (See Details)
Published: 2003
Direct-to-consumer advertising of prescription drugs: whatever the problem, you can always pop a pill  
http://www.cwhn.ca/sites/default/files/PDF/CEWH/RB/bulletin-vol3no2EN.pdf

Examines the effects of direct-to-consumer advertising (DTCA) of pharmaceuticals.

 (See Details)
Published: 2003
Women's health protection  
http://www.cwhn.ca/sites/default/files/network-reseau/fall98/fall98index.html

Discusses how many safety regulations governing what types of drugs and medical devices can be sold in Canada provide a backdrop to many key concerns raised by women's health groups.

 (See Details)
Published: 1998
Drug regulatory failure in Canada: the case of Diane-35  
http://www.whp-apsf.ca/en/documents/diane35.html

Criticizes federal prescription drug regulation using Diane-35 (cyproterone acetate and ethinyl estradiol) as an example.

 (See Details)
Published: 2004
The marketization of depression: the prescribing of SSRI antidepressants to women  
http://www.whp-apsf.ca/pdf/SSRIs.pdf

Looks at the impact of SSRI use among Canadian women. Reviews what is currently known about the benefits and harms caused by SSRIs, as well as both the definition and incidence of depression in women.

 (See Details)
Published: 2005
Transparency and the drug approval process at Health Canada: policy brief  
http://www.whp-apsf.ca/en/documents/trans_policy.html

Argues that the lack of transparency in the drug approval process can lead to inappropriate, unnecessary and sometimes dangerous drug use, and it impedes the development of knowledge and appropriate decision-making.

 (See Details)
Published: 2006